Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin

NCT00565500

Last updated date
Study Location
Ce.S.I., Center of Excellence on Aging, G. d'Annunzio University
Chieti, CH, 66100, Italy
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ischemic Heart Disease, Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. male or female, age 18-75;

2. subjects with osteoarthritis and documented stable ischemic heart disease;

3. the patient is on long-term aspirin prophylaxis for the ischemic condition;

4. the patient requires or is eligible for chronic treatment with an antiinflammatory and/or analgesic drugs given to control osteoarthritis symptoms;

5. female subjects of childbearing potential must have a negative pregnancy test, use adequate contraception during the study and not be lactating;

6. written informed consent before undergoing any study procedure.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. active gastrointestinal disease (e.g. Crohn's disease or ulcerative colitis) or any
evidence of concomitant disease which may lead to early termination of the study;


2. history of active peptic ulceration, gastrointestinal bleeding, esophageal, gastric or
duodenal ulcer;


3. known hypersensitivity to COX-2 inhibitors, analgesics, antipyretics, sulfonamides or
NSAIDs;


4. treatment with any investigational drug within the previous 30 days;


5. previous participation in this study;


6. evidence of neoplasm or any other severe disease of any organ, including any
psychiatric illness;


7. clinically relevant deviations from the normal range in laboratory tests;


8. recent history or suspicion of alcohol abuse or drug addiction;


9. subjects unlikely to be collaborative or to give reliable answers;


10. pregnancy or lactation; female or childbearing potential without a clinical accepted
contraceptive method;


11. any severe pathology that can interfere with the treatment or the clinical or
instrumental tests of the trial;


12. intake of antiaggregant, anticoagulant, diuretic, beta-blocker, ACE- inhibitor,
lithium, methotrexate, cimetidine, digoxin;


13. contraindications to NSAIDs.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Ischemic Heart Disease, OsteoarthritisCelecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
NCT00565500
  1. Chieti, CH
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
Official Title  ICMJE A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.
Brief Summary Study design: Single center, placebo-controlled, double blind, parallel groups. To evaluate the potential interaction between aspirin and ibuprofen or celecoxib in patients with osteoarthritis (OA) and documented stable ischemic heart disease, a total of 24 patients chronically treated with aspirin will be randomly assigned to one of the 3 treatment groups: 1) celecoxib 200 mg bid; 2) ibuprofen 600 mg tid; 3) placebo.
Detailed Description Patients with arthritis and vascular disease may receive both NSAIDs and lowdose aspirin for the secondary prevention of important vascular events. The use of COX-2 inhibitors may have the potential advantage vs. nonselective NSAIDs in reducing the probability of interfering with permanent inactivation of COX-1 platelet by low-dose aspirin, in this setting. In fact, recent studies suggest that the likelihood of COX-inhibitors to present this pharmacodynamic interaction is inversely related to their COX-2 selectivity. Thus, differently from the non-selective NSAID ibuprofen, prior administration of the selective COX-2 inhibitor rofecoxib, does not antagonize the irreversible inhibition induced by aspirin in healthy subjects. Aim of this study is to determine whether celecoxib given at therapeutic dose at steady state alters the antiplatelet activity of low-dose aspirin, in comparison with ibuprofen.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Condition  ICMJE
  • Ischemic Heart Disease
  • Osteoarthritis
Intervention  ICMJE
  • Drug: celecoxib
    celecoxib capsules 200 mg bid for 1 week
  • Drug: ibuprofen
    ibuprofen tablets 600 mg tid for 1 week
  • Drug: placebo
    placebo capsules tid for 1 week
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: celecoxib
  • Experimental: 2
    Intervention: Drug: ibuprofen
  • Placebo Comparator: 3
    Intervention: Drug: placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 29, 2007)
24
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. male or female, age 18-75;
  2. subjects with osteoarthritis and documented stable ischemic heart disease;
  3. the patient is on long-term aspirin prophylaxis for the ischemic condition;
  4. the patient requires or is eligible for chronic treatment with an antiinflammatory and/or analgesic drugs given to control osteoarthritis symptoms;
  5. female subjects of childbearing potential must have a negative pregnancy test, use adequate contraception during the study and not be lactating;
  6. written informed consent before undergoing any study procedure.

Exclusion Criteria:

  1. active gastrointestinal disease (e.g. Crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study;
  2. history of active peptic ulceration, gastrointestinal bleeding, esophageal, gastric or duodenal ulcer;
  3. known hypersensitivity to COX-2 inhibitors, analgesics, antipyretics, sulfonamides or NSAIDs;
  4. treatment with any investigational drug within the previous 30 days;
  5. previous participation in this study;
  6. evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness;
  7. clinically relevant deviations from the normal range in laboratory tests;
  8. recent history or suspicion of alcohol abuse or drug addiction;
  9. subjects unlikely to be collaborative or to give reliable answers;
  10. pregnancy or lactation; female or childbearing potential without a clinical accepted contraceptive method;
  11. any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial;
  12. intake of antiaggregant, anticoagulant, diuretic, beta-blocker, ACE- inhibitor, lithium, methotrexate, cimetidine, digoxin;
  13. contraindications to NSAIDs.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00565500
Other Study ID Numbers  ICMJE 635-IFL-0508-017
N49-98-71-900
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Raffaele De Caterina, MD, PhD, G. d'Annunzio University - Chieti
Study Sponsor  ICMJE University of Chieti
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Raffaele De Caterina, MD, PhDInstitute of Cardiology, G. d'Annunzio University
PRS Account G. d'Annunzio University
Verification Date November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP